IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Groesdonk, H. V.
Right arrow Articles by Senftleben, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groesdonk, H. V.
Right arrow Articles by Senftleben, U.

 Previous Article  |  Next Article 

Infection and Immunity, October 2006, p. 5989-6000, Vol. 74, No. 10
0019-9567/06/$08.00+0     doi:10.1128/IAI.00138-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Escherichia coli Prevents Phagocytosis-Induced Death of Macrophages via Classical NF-{kappa}B Signaling, a Link to T-Cell Activation

Heinrich V. Groesdonk,{dagger} Silke Schlottmann,{dagger} Friederike Richter, Michael Georgieff, and Uwe Senftleben*

Department of Anesthesiology and Intensive Care, University of Ulm, Ulm, Germany

Received 26 January 2006/ Returned for modification 30 March 2006/ Accepted 20 July 2006

NF-{kappa}B is a crucial mediator of macrophage inflammatory responses, but its role in the context of pathogen-induced adaptive immune responses has yet to be elucidated. Here, we demonstrate that classical NF-{kappa}B activation delays phagocytosis-induced cell death (PICD) in Raw 264.7 and bone marrow-derived macrophages (BMDMs) upon ingestion of bacteria from the Escherichia coli laboratory strain Top10. By expression of a nondegradable form of I{kappa}B{alpha} (superrepressor) and pyrrolidine dithiocarbamate treatment, prolonged activation of NF-{kappa}B upon bacterial coculture is suppressed, whereas initial induction is only partially inhibited. This activation pattern results in partial inhibition of cellular activation and reduced expression of costimulatory CD86. Notably, suppression of classical NF-{kappa}B activation does not influence bacterial uptake rates but is followed by increased production of oxygen radicals and enhanced intracellular killing in Raw macrophages. This is associated with reduced expression of NF-{kappa}B-dependent antiapoptotic c-IAP-2 and a loss of the mitochondrial transmembrane potential. Accordingly, NF-{kappa}B inhibition in Raw cells and BMDMs causes increased apoptotic rates within 12 h of bacterial ingestion. Interestingly, accelerated eradication of E. coli in NF-{kappa}B-inhibited macrophages is associated with reduced antigen-specific T-cell activation in macrophage-lymphocyte cocultures. These data suggest that E. coli inhibits PICD of macrophages via classical, antiapoptotic NF-{kappa}B activation and thus facilitates signaling to T cells. Subsequently, a proper adaptive immune response is likely to be generated. Conclusively, therapeutic inhibition of classical NF-{kappa}B activation in macrophages may hamper the initiation of adaptive immunity.


* Corresponding author. Mailing address: Department of Anesthesiology and Intensive Care, University of Ulm, Steinhövelstr. 9, D-89075 Ulm, Germany. Phone: 49 731 50060086. Fax: 49 731 50026755. E-mail: uwe.senftleben{at}uni-ulm.de.

Editor: F. C. Fang

{dagger} Heinrich V. Groesdonk and Silke Schlottmann contributed equally to this work.


Infection and Immunity, October 2006, p. 5989-6000, Vol. 74, No. 10
0019-9567/06/$08.00+0     doi:10.1128/IAI.00138-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2006 by the American Society for Microbiology. All rights reserved.